DLBCL CD20+ ImbruVeRCHOP-Trial (#757)
Laufzeit: 01.01.2019 - 31.12.2040
Kurzfassung
Ibrutinib (Imbruvica), Bortezomib (Velcade) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI >= 2
ImbruVeRCHOP
